The prophylactic antiemetic efficacy of prochlorperazine and ondansetron in nasal septal surgery: a randomized double-blind comparison.
A prospective, randomized placebo-controlled study was undertaken to compare the effects on heart rate and blood pressure during surgery and on the incidence of nausea, vomiting and headache after surgery of i.m. prochlorperazine 0.2 mg.kg-1, i.v. prochlorperazine 0.1 mg.kg-1 and i.v. ondansetron 0.06 mg.kg-1 given at induction of general anaesthesia to patients undergoing septorhinoplasty. The effects of the test drugs after administration on heart rate and blood pressure were similar, as were the incidences of retching and vomiting in the recovery ward after each test drug. Postoperatively, compared with placebo (7%), nausea per se was most frequent in those given i.v. prochlorperazine (25%, P < 0.01), and less frequent in those given i.m. prochlorperazine (2%) and i.v. ondansetron (15%). Vomiting per se was reduced from 24% to 7% (P < 0.025) by i.v. prochlorperazine and to 4% (P < 0.0005) by i.v. ondansetron. The incidence of nausea with vomiting was reduced from 35% to 15% (P < 0.025). 16% (P < 0.05) and 11% (P < 0.005) by i.m. prochlorperazine, i.v. prochlorperazine and i.v. ondansetron respectively. I.m. prochlorperazine and i.v. ondansetron increased the frequency (from 35% to 64%, P < 0.0005 and to 71%, P < 0.0005, respectively) of those experiencing no PONV and delayed the onset of PONV, but only i.m. prochlorperazine reduced the severity of postoperative vomiting. Headache was frequent in the control (69%), i.v. prochlorperazine (62%) and i.v. ondansetron (69%) groups, and least frequent after i.m. prochlorperazine (53%; P < 0.05 versus i.v. ondansetron). It is concluded that these drugs have no adverse cardiovascular effects within 10 minutes of administration, i.m. prochlorperazine and i.v. ondansetron reduce PONV more effectively than i.v. prochlorperazine and postoperative headache after septorhinoplasty occurs less frequently in those given i.m. prochlorperazine than in those given i.v. ondansetron.
van den Berg
A A
AA
Department of Anaesthesia, Riyadh Armed Forces Hospital, Kingdom of Saudi Arabia.
D000293:Adolescent; D000328:Adult; D000768:Anesthesia, General; D000932:Antiemetics / Q000008:administration & dosage / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002648:Child; D004311:Double-Blind Method; D005260:Female; D006261:Headache / Q000209:etiology / Q000517:prevention & control; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D015994:Incidence; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009300:Nasal Septum / Q000601:surgery*; D009325:Nausea / Q000209:etiology / Q000517:prevention & control; D017294:Ondansetron / Q000008:administration & dosage / Q000627:therapeutic use*; D010919:Placebos; D011183:Postoperative Complications / Q000517:prevention & control; D011346:Prochlorperazine / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D012225:Rhinoplasty / Q000009:adverse effects; D014839:Vomiting / Q000209:etiology / Q000517:prevention & control
D000932:Antiemetics; D010919:Placebos; D017294:Ondansetron; D011346:Prochlorperazine